The most common AEs in the blonanserin groups (incidence ≥5%) can be classified as (1) a type with a high incidence compared with the placebo group, occurring dose dependently (extrapyramidal symptoms, somnolence, and increased prolactin level) or (2) a type with a similar incidence to the placebo group (nausea, headache, worsening schizophrenia, and skin abrasion). The gene discussed is PRL; the disease is schizophrenia.